IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v8y2024i2d10.1007_s41669-023-00467-2.html
   My bibliography  Save this article

From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy

Author

Listed:
  • Elvio Emanuele Rossini

    (Pharmalex Italy Spa)

  • Carlotta Galeone

    (Università degli Studi di Milano-Bicocca
    Pharmalex Italy Spa)

  • Chiara Lucchetti

    (Pharmalex Italy Spa)

  • Claudio Jommi

    (Università del Piemonte Orientale)

Abstract

Background New indications for existing medicines are increasing over time. In most countries, drug pricing and reimbursement conditions are renegotiated every time a new indication is approved. There is a growing interest in the price negotiation model for new indications, specifically comparing an indication-based versus blended approach. However, little evidence currently exists regarding the complexity of these negotiations and their impact on actual prices. Italy has recently transitioned from an indication-based approach to a blended price model. This study aims to measure the impact of price and reimbursement negotiation of new indications on discounts (i.e. actual prices) and on the negotiation duration, used as a proxy of its complexity. Methods We considered new indications approved through a European centralized procedure from January 2013 to March 2022 for which the price and reimbursement status was approved in Italy between January 2015 and March 2022, amounting to 52 new indications. Data on the timeframe of the Italian price and reimbursement process and its phases were obtained from publicly available sources. Discounts for the first indication and their subsequent increases for new indications were estimated by comparing ex-factory prices and tendered prices. To calculate p-values, we employed the Mann–Whitney test, and multiple regression models were utilized to examine correlations between negotiation time and the characteristics of the medicines. Results The mean time to reimbursement was 603 days, in contrast to 583 days for the first launch. Price negotiation took longer for rare diseases, cancer drugs, and in case of therapies with minor added therapeutic value. On average, the additional discount (on top of discounts for prior indications) was 13%, significantly lower than the mean discount for the first indications approved (24.9%). The discounts increment was lower, but negotiation took longer if a Managed Entry Agreement accompanied the final agreement. Additionally, discounts have increased over the years. Conclusion The negotiation for new indications takes longer than the first one, and provides, on average, an additional discount of 13%. While our findings bear the potential for significant policy implications, they necessitate prudent interpretation due to a limited number of observations. The increasing trend in additional discounts over time applied to all indications in recent negotiations, may suggest a descending trend of value for new indications and a shift from an indication-based pricing approach to a blended model. Otherwise, budget impact considerations might have outweighed a value-based approach in the recent negotiations. If so, two potential options for restoring a value-based approach are returning to an indication-based pricing or giving explicit and higher weight to value within a blended model.

Suggested Citation

  • Elvio Emanuele Rossini & Carlotta Galeone & Chiara Lucchetti & Claudio Jommi, 2024. "From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy," PharmacoEconomics - Open, Springer, vol. 8(2), pages 251-261, March.
  • Handle: RePEc:spr:pharmo:v:8:y:2024:i:2:d:10.1007_s41669-023-00467-2
    DOI: 10.1007/s41669-023-00467-2
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-023-00467-2
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-023-00467-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Riccaboni, Massimo & Swoboda, Torben & Van Dyck, Walter, 2022. "Pharmaceutical net price transparency across european markets: Insights from a multi-agent simulation model," Health Policy, Elsevier, vol. 126(6), pages 534-540.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Maria Grazia Ursino & Annalisa Milano & Filippo Viti Angelis & Eva Alessi & Francesco Trotta, 2025. "Pricing for Multi-Indication Drugs in the Italian Regulatory Context," PharmacoEconomics - Open, Springer, vol. 9(3), pages 415-422, May.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:8:y:2024:i:2:d:10.1007_s41669-023-00467-2. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.